The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.
Nancy D Doolittle, Lauren E Abrey, Nicolay Ferrari, Walter A Hall, Edward R Laws, Roger E McLendon, Leslie L Muldoon, David Peereboom, Darryl R Peterson, C Patrick Reynolds, Peter Senter, and Edward A Neuw... more elt. less
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road-L603, Portland, OR 97201-3098, USA.
Clin Cancer Res. 2002 Jun 1; 8 (6): 1702-9.
AbstractThe November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.